CDP-17: [Funding] SK-Channels

One liner: The SK -channel project is developing a small molecule positive allosteric modulator drug for small-conductance calcium-activated potassium (SK) channels for the treatment of ataxia and related tremors, with a potential for other CNS and peripheral indications.

Cerebrum DAO Deal Team

• Senior reviewers: Brett Abrahams (Neuroscience), Peter Groenen (Translational Science)
• Project Team: Peter Groenen, Maryna Polyakova, Brian Magierski
• Sourced by: Brian Magierski

Project Team

• Principal Investigator: Peter Groenen, PhD
• Translational Neuroscience Advisor: Brett Abrahams, PhD
• Project Team: Maryna Polyakova MD/PhD
• Preclinical Development advisor: Naheed (MAX) Rohman Mirza, PhD

Approval

Cerebrum DAO seeks community approval to execute an exclusive option agreement with Chapman University for the Intellectual Property rights for the SK Channels project defined below and authorization to fund the proposed replication study, estimated up to $65,000 of investment. With approval, Cerebrum will mint the SK Channels project and associated agreement into an IP-NFT, execute the agreement and begin the replication study. Following successful replication, Cerebrum will decide whether to fund all of the next phase of work or whether to raise all or part of the next phase through an IPT fundraise and seek further approval through a new governance vote.

Please visit the following link to view the full proposal, as the proposal content exceeds Snapshot's character limits and includes unsupported formatting: https://docs.google.com/document/d/1b77rkaZkQ7D4cGqIKLBLk9-VDnnodicMWH7AsdF-rhI/edit?usp=sharing